Understanding how inflammation affects muscle function in older adults
Mechanisms of Anabolic Resistance in Older Humans
This study is testing how long-term inflammation affects muscle function and exercise responses in older adults compared to younger adults.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 21 Years to 85 Years |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT06617195 on ClinicalTrials.gov |
What this trial studies
This research aims to explore the impact of chronic inflammation on muscle function and exercise responses in older adults. It hypothesizes that inflamed adipose tissue secretes factors that activate inflammatory pathways in skeletal muscle, potentially disrupting exercise-responsive mechanisms. The study will involve both young and older adults who will undergo assessments of molecular responses to acute exercise, including protein synthesis rates and gene activation in skeletal muscle. Additionally, adipose tissue will be evaluated through non-invasive imaging and biopsies to determine its influence on muscle function and anabolic responses to exercise.
Who should consider this trial
Good fit: Ideal candidates for this study are older adults who are physically active and do not have chronic inflammatory conditions.
Not a fit: Patients with diabetes, obesity, or significant chronic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved exercise strategies for older adults, enhancing their muscle function and overall health.
How similar studies have performed: Other studies have indicated that addressing inflammation can improve muscle function, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Exclusion Criteria: 1. Diabetes or fasting plasma glucose 126 mg/dL 2. Body mass index (BMI) 30 kg/m2 3. Anemia (female subjects hemoglobin of \<11 g/dl and male subjects hemoglobin \<12 g/dl) 4. Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment) 5. Renal failure (serum creatinine \> 1.5mg/dl) 6. Chronic active liver disease (AST\>144IU/L or ALT\>165IU/L) 7. Oral warfarin group medications or history of blood clotting disorders. 8. Smoking 9. Pregnancy or breastfeeding 10. Alcohol consumption greater than 2 glasses/day or other substance abuse 11. Untreated or uncontrolled hypothyroidism 12. Debilitating chronic disease (at the discretion of the investigators)
Where this trial is running
Rochester, Minnesota
- Mayo Clinic — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Ian Lanza — Mayo Clinic
- Study coordinator: Rachel Passehl
- Email: passehl.rachel@mayo.edu
- Phone: 507-255-8112
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.